MX394620B - Composicion farmaceutica y metodo para preparar el mismo - Google Patents
Composicion farmaceutica y metodo para preparar el mismoInfo
- Publication number
- MX394620B MX394620B MX2019015612A MX2019015612A MX394620B MX 394620 B MX394620 B MX 394620B MX 2019015612 A MX2019015612 A MX 2019015612A MX 2019015612 A MX2019015612 A MX 2019015612A MX 394620 B MX394620 B MX 394620B
- Authority
- MX
- Mexico
- Prior art keywords
- preparing
- same
- pharmaceutical composition
- solid dispersion
- carrier material
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una dispersión sólida, un método para prepararla, y una preparación sólida que comprende la dispersión sólida. La dispersión sólida contiene (R)-4-amino-1-(1-(but-2-inoil)pirrolidin-3-il)-3-(4-(2,6-difluorofenoxi)fenil)-1,6-dihidro-7H-pirrolo[2,3-d]piridazin-7-ona o una de sus sales farmacéuticamente aceptables, y un material de soporte. El material de soporte se selecciona de succinato de acetato de hidroxipropilmetilcelulosa y ftalato de hidroxipropilmetilcelulosa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710536705 | 2017-07-04 | ||
| CN201711105075 | 2017-11-10 | ||
| PCT/CN2018/094211 WO2019007317A1 (zh) | 2017-07-04 | 2018-07-03 | 一种药物组合物及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019015612A MX2019015612A (es) | 2020-02-26 |
| MX394620B true MX394620B (es) | 2025-03-24 |
Family
ID=64950432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019015612A MX394620B (es) | 2017-07-04 | 2018-07-03 | Composicion farmaceutica y metodo para preparar el mismo |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11304945B2 (es) |
| EP (1) | EP3650025A4 (es) |
| JP (1) | JP7190452B2 (es) |
| KR (1) | KR102697985B1 (es) |
| CN (1) | CN109963565B (es) |
| AU (1) | AU2018296476B2 (es) |
| BR (1) | BR112019027473A2 (es) |
| CA (1) | CA3066046A1 (es) |
| MX (1) | MX394620B (es) |
| MY (1) | MY199479A (es) |
| RU (1) | RU2767872C2 (es) |
| TW (1) | TWI837095B (es) |
| UA (1) | UA127413C2 (es) |
| WO (1) | WO2019007317A1 (es) |
| ZA (1) | ZA201908090B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111499642A (zh) * | 2019-01-31 | 2020-08-07 | 江苏恒瑞医药股份有限公司 | 吡咯并[2,3-d]哒嗪-7-酮类衍生物的可药用盐、晶型及其制备方法 |
| TW202100527A (zh) | 2019-05-31 | 2021-01-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種固體分散體及其製備方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1926476E (pt) * | 2005-08-29 | 2013-07-10 | Sanofi Aventis Us Llc | Dispersões sólidas amorfas de 7-cloro-n,n,5-trimetil-4-oxo-3- fenil-3,5-di-hidro-4h-piridazino[4,5-b]indole-1-acetamida |
| JP2010526848A (ja) | 2007-05-11 | 2010-08-05 | エフ.ホフマン−ラ ロシュ アーゲー | 難溶性薬物用の医薬組成物 |
| JP2013103899A (ja) | 2011-11-11 | 2013-05-30 | Fuji Chem Ind Co Ltd | 難溶性薬物の新規な固体分散体 |
| MA37711A1 (fr) | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| NZ708272A (en) * | 2013-01-22 | 2020-07-31 | Hoffmann La Roche | Pharmaceutical composition with improved bioavailability |
| CN105899212A (zh) | 2013-08-06 | 2016-08-24 | 翁科埃斯克斯有限公司 | 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法 |
| KR102073797B1 (ko) | 2014-07-07 | 2020-02-05 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 단백질 키나제 저해제로서의 아미노피리다지논 화합물 |
| US9545407B2 (en) * | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
| MX2017011469A (es) | 2015-03-10 | 2018-01-23 | Shionogi Inc | Dispersiones sólidas. |
-
2018
- 2018-07-03 KR KR1020207001561A patent/KR102697985B1/ko active Active
- 2018-07-03 RU RU2020102280A patent/RU2767872C2/ru active
- 2018-07-03 UA UAA202000414A patent/UA127413C2/uk unknown
- 2018-07-03 WO PCT/CN2018/094211 patent/WO2019007317A1/zh not_active Ceased
- 2018-07-03 CA CA3066046A patent/CA3066046A1/en active Pending
- 2018-07-03 US US16/626,910 patent/US11304945B2/en not_active Expired - Fee Related
- 2018-07-03 AU AU2018296476A patent/AU2018296476B2/en not_active Ceased
- 2018-07-03 MX MX2019015612A patent/MX394620B/es unknown
- 2018-07-03 CN CN201880004396.3A patent/CN109963565B/zh active Active
- 2018-07-03 BR BR112019027473-1A patent/BR112019027473A2/pt active Search and Examination
- 2018-07-03 JP JP2019568286A patent/JP7190452B2/ja active Active
- 2018-07-03 EP EP18828577.9A patent/EP3650025A4/en not_active Withdrawn
- 2018-07-03 MY MYPI2019007710A patent/MY199479A/en unknown
- 2018-07-04 TW TW107123108A patent/TWI837095B/zh active
-
2019
- 2019-12-05 ZA ZA2019/08090A patent/ZA201908090B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UA127413C2 (uk) | 2023-08-16 |
| TW201906609A (zh) | 2019-02-16 |
| US20200171031A1 (en) | 2020-06-04 |
| MY199479A (en) | 2023-11-01 |
| AU2018296476B2 (en) | 2023-11-02 |
| RU2767872C2 (ru) | 2022-03-22 |
| BR112019027473A2 (pt) | 2020-07-07 |
| JP7190452B2 (ja) | 2022-12-15 |
| RU2020102280A3 (es) | 2021-09-17 |
| KR102697985B1 (ko) | 2024-08-23 |
| TWI837095B (zh) | 2024-04-01 |
| KR20200024237A (ko) | 2020-03-06 |
| CN109963565A (zh) | 2019-07-02 |
| ZA201908090B (en) | 2021-08-25 |
| RU2020102280A (ru) | 2021-08-04 |
| CN109963565B (zh) | 2021-09-03 |
| EP3650025A4 (en) | 2021-04-28 |
| JP2020525415A (ja) | 2020-08-27 |
| AU2018296476A1 (en) | 2020-01-16 |
| WO2019007317A1 (zh) | 2019-01-10 |
| EP3650025A1 (en) | 2020-05-13 |
| MX2019015612A (es) | 2020-02-26 |
| CA3066046A1 (en) | 2019-01-10 |
| US11304945B2 (en) | 2022-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201902053B (en) | Pharmaceutical composition | |
| MX2020012969A (es) | Combinacion y composicion farmaceutica y preparacion combinada que contiene activador de glucocinasa y farmaco hipoglucemico biguanida, asi como metodo de preparacion y uso del mismo. | |
| EP3753943A4 (en) | HETEROCYCLIC COMPOUND, ITS APPLICATION AND PHARMACEUTICAL COMPOSITION CONSISTING OF IT | |
| MX384545B (es) | Composicion farmaceutica | |
| MX2016012058A (es) | 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procedimientos para su preparacion. | |
| MX2021010022A (es) | Composicion farmaceutica. | |
| ZA201902052B (en) | Pharmaceutical composition | |
| ZA201902049B (en) | Pharmaceutical composition | |
| EP3845528C0 (en) | PYRAZOLE COMPOUNDS, CORRESPONDING PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS IRAK4 INHIBITORS | |
| MY190849A (en) | Methods of treating multiple sclerosis | |
| EP3882247A4 (en) | SIX-MEMBERED, SIX-MEMBERED, HETEROCYCLIC COMPOUND AND USES OF THEREOF AS A PROTEIN KINASE RECEPTOR INHIBITOR | |
| PH12020550125A1 (en) | Crystalline forms of 3-substituted 1,2,4-oxadiazole | |
| MX2018015872A (es) | Derivados de benzodioxano y su uso farmaceutico. | |
| MX2018013573A (es) | Ciertos inhibidores de la proteína cinasa. | |
| GB2590189B (en) | Lycorine derivative, and pharmaceutical composition and use thereof | |
| UY30121A1 (es) | Nuevos compuestos | |
| MX2020002505A (es) | Compuestos heteroaromaticos sustituidos con cicloolefinas y su uso. | |
| EP3838897A3 (en) | (hetero)arylamide compound for inhibiting protein kinase activity | |
| MX2023001805A (es) | Formas solidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-n- bencilacetamida. | |
| MY199479A (en) | Pharmaceutical composition and method for preparing same | |
| JOP20210063A1 (ar) | مشتقات جديدة من أمينو- بيريميدونيل- بيبريدينيل، وعملية لتحضيرها وتركيبات صيدلانية تحتوي عليها | |
| WO2017046228A3 (en) | Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof | |
| ZA201804663B (en) | C-glycoside derivatives having fused phenyl ring or pharmaceutically acceptable salts thereof, method for preparing the same and pharmaceutical composition comprising the same | |
| PH12016500134B1 (en) | 1-(piperazin-1-yl) -2- ([1,2,4] triazol -1- yl) - ethanone derivatives | |
| WO2017046227A3 (en) | Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof |